Skip to main content

PR Newswire: Jennifer Doudna, Ph.D., and Emmanuelle Charpentier, Ph.D., Win 2014 Dr. Paul Janssen Award for Biomedical Research

June 24, 2014

Their collaboration led to the discovery of a new method for precisely manipulating genetic information in ways that should produce new insights in health and disease, and may lead to the discovery of new targets for drug development.

Forbes: Gene Therapy's Big Comeback

March 26, 2014

Elliott Sigal earned a reputation at Bristol-Myers Squibb as one of the drug industry’s best research chiefs. His bets on risky technologies like cancer immunotherapy and new types of diabetes drugs helped Bristol turn from a laggard into a growth stock. But there was one technology he wouldn’t touch: gene therapy, which tries to use engineered viruses to defeat disease at the DNA level.

The New York Times: A Powerful New Way to Edit DNA

March 3, 2014

In the late 1980s, scientists at Osaka University in Japan noticed unusual repeated DNA sequences next to a gene they were studying in a common bacterium. They mentioned them in the final paragraph of a paper: “The biological significance of these sequences is not known.”

FNIH: Foundation for the NIH to Award Lurie Prize in the Biomedical Sciences to Jennifer Doudna from UC Berkeley

February 4, 2014

The Foundation for the National Institutes of Health (FNIH) has selected Jennifer Doudna, Ph.D., a Professor from the University of California, Berkeley, as the second winner of its Lurie Prize in the Biomedical Sciences.

Forbes: Rachel Haurwitz named to Forbes' 30 Under 30 list for Science and Healthcare

January 14, 2014

It's the most promising genetic engineering tool in years: a protein called Cas9, culled from a bacterial system called CRISPR that is used to destroy invading viruses.